en · de · es · pt
aod-9604-notes.peptides6608.com › Data › Background And Development History — Research Overview

Background And Development History — Research Overview

By Editorial Desk · published 2026-01-07 · last reviewed 2026-02-25 · Data

This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-02-25. Anything still debated is marked as such rather than presented as settled.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from C-terminal region of human growth hormone
Approximate molecular massAbout 1.8 kDaVaries with sequence length and counterions
Confirmed receptor targetNone establishedNo confirmed growth hormone receptor agonism
Reported in vitro activityLipolysis stimulation and lipogenesis inhibitionObserved mainly in adipocyte models; human relevance uncertain
Regulatory statusNot approved as a drug in major marketsMay be treated differently across jurisdictions; not a recognized dietary ingredient in some countries

Identity and Research Context

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Related pages on this site

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Further detail

=== Time and temperature indicators === Temperature indicators show that a specified temperature has been reached or exceeded. Time–temperature indicators respond to cumulative exposure over time and can provide an indication of the thermal history of a product. Indicators may use chemical, enzymatic, microbial, mechanical, electronic, or colour-changing mechanisms. They are used with foods, vaccines, pharmaceuticals, biological materials, and other temperature-sensitive goods. Electronic temperature data loggers can record the time, duration, and extent of temperature deviations. Thermochromic inks provide reversible or irreversible colour changes when particular temperatures are reached.

m2 or 131.2 hectares. In a graphene sheet, each atom is connected to its three nearest carbon neighbors by σ-bonds, and a delocalized π-bond, which contributes to a valence band that extends over the whole sheet. This type of bonding is also seen in polycyclic aromatic hydrocarbons. The valence band is touched by a conduction band, making graphene a semimetal with unusual electronic properties that are best described by theories for massless relativistic particles. Charge carriers in graphene show linear, rather than quadratic, dependence of energy on momentum, and field-effect transistors with graphene can be made that show bipolar conduction. Charge transport is ballistic over long distances; the material exhibits large quantum oscillations and large nonlinear diamagnetism.

The authors conclude that past respiratory disorders maximally contribute to IPF risk, followed by known IPF comorbidities, metabolic diseases, cardiovascular abnormalities, and diseases of the eye, with the overall pattern of the importance ranking substantially invariant across the sexes.

Pellagra can be common in people who obtain most of their food energy from corn, notably rural South America, where maize is a staple food. If maize is not nixtamalized, it is a poor source of tryptophan, as well as niacin. Nixtamalization corrects the niacin deficiency and is a common practice in Native American cultures that grow corn, but most especially in Mexico and the countries of Central America. Following the corn cycle, the symptoms usually appear during spring, increase in the summer due to greater sun exposure, and return the following spring. Pellagra was once common in the poorer states of the U.S. South, such as Mississippi and Alabama, where its cyclical appearance in the spring after meat-heavy winter diets led to it being known as "spring sickness" (particularly when it appeared among more vulnerable children), as well as among the residents of jails and orphanages as studied by Dr. Joseph Goldberger. Pellagra is common in Africa, Indonesia, and China. In affluent societies, most patients with clinical pellagra are poor, homeless, alcohol-dependent, or psychiatric patients who refuse food. Pellagra was common among prisoners of Soviet labor camps (the Gulags). In addition, pellagra, as a micronutrient deficiency disease, frequently affects populations of refugees and other displaced people due to their unique, long-term residential circumstances and dependence on food aid.

The association of a protein with a lipid bilayer may involve significant changes within tertiary structure of a protein. These may include the folding of regions of protein structure that were previously unfolded or a re-arrangement in the folding or a refolding of the membrane-associated part of the proteins. It also may involve the formation or dissociation of protein quaternary structures or oligomeric complexes, and specific binding of ions, ligands, or regulatory lipids. Typical amphitropic proteins must interact strongly with the lipid bilayer in order to perform their biological functions. These include the enzymatic processing of lipids and other hydrophobic substances, membrane anchoring, and the binding and transfer of small nonpolar compounds between different cellular membranes. These proteins may be anchored to the bilayer as a result of hydrophobic interactions between the bilayer and exposed nonpolar residues at the surface of a protein, by specific non-covalent binding interactions with regulatory lipids , or through their attachment to covalently bound lipid anchors. It has been shown that the membrane binding affinities of many peripheral proteins depend on the specific lipid composition of the membrane with which they are associated.

Sources: en.wikipedia.org

Supporting material

These two are the heaviest isotopes of dubnium to date, and both were produced as a result of decay of the heavier nuclei 288Mc and 294Ts rather than directly, because the experiments that yielded them were originally designed in Dubna for 48Ca beams. For its mass, 48Ca has by far the greatest neutron excess of all practically stable nuclei, both quantitative and relative, which correspondingly helps synthesize superheavy nuclei with more neutrons, but this gain is compensated by the decreased likelihood of fusion for high atomic numbers.

The United States accused Maduro of electoral fraud and presiding over a "narco-state". In March 2020, during Trump's first term, the United States Justice Department indicted Maduro on cocaine-trafficking conspiracy charges, which Maduro denied. Trump designated two Venezuelan drug gangs, the Tren de Aragua and the Cartel of the Suns, as Foreign Terrorist Organizations (FTOs) in January and July 2025 respectively, and alleged that the latter was led by Maduro. Maduro denied being involved in cartel leadership and characterized the designations as an attempt to use the war on drugs for regime change. Some Latin American crime experts have described the Cartel of the Suns as more of a general network of Venezuelan government and military corruption than as an organized group. Also in July 2025, a secret order instructed the US military to use force against cartels listed as terrorist organizations. In August 2025, the reward for Maduro's arrest increased to $50 million with US attorney general Pam Bondi calling Maduro "one of the largest narco-traffickers in the world and a threat to our national security." However, the Associated Press reported in January 2026 that while the US government has never publicly accused Delcy Rodríguez of criminal wrongdoing related to the drug trade, the Drug Enforcement Administration has nonetheless gathered an extensive intelligence file on Rodríguez since 2018 and designated her as a "priority target" in 2022—which the agency does for individuals suspected of having "significant impact" on the drug trade.

Parmotrema perlatum has a thallus that ranges from loosely to tightly attached to the surface it grows on, forming expansive, spreading colonies that often merge together. Individual thalli typically measure up to 10–15 cm (4–6 in) in diameter. The upper thallus surface is greenish-grey, blue-grey, or yellowish-grey in colour, lacking pruina and either free of spots (maculae), or with few maculae. This species develops soredia, a type of asexual reproductive structure, aiding in its propagation. The lobes of this lichen vary from 1.5 to 10 mm in width, with a wave-like (undulate) or ruffled pattern and overlapping (imbricate) arrangement. The tips and edges of these lobes are generally smooth and round, sometimes notched (crenate) or incised, often curling up or inward, revealing the paler brown to black underside adorned with hair-like structures (cilia) up to 2.5 mm in length. Rhizines are common on the underside of the thallus, except for a brown border near the edges. The soredia found in this species are granular and appear white or may become grey due to wear. They are located within specifically structured groups called soralia, which can be linear to oval in shape, often positioned at the edges of the lobes. The presence of soredia causes the lobe margins to curl back and form capitate soralia. The upper surface of the lichen is typically whitish grey to pale greenish-grey, and can be either smooth or slightly wrinkled, without spots (immaculate), featuring scattered, shallow cracks. Isidia are absent in this species.

== Further reading == Dean L (2012). "Omeprazole Therapy and CYP2C19 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520353. Bookshelf ID: NBK100895.

=== Draining === Once the cheese curd is judged to be ready, the cheese whey must be released. As with many foods the presence of water and the bacteria in it encourages decomposition. To prevent such decomposition it is necessary to remove most of the water (whey) from the cheese milk, and hence cheese curd, to make a partial dehydration of the curd. There are several ways to separate the curd from the whey.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Is AOD9604 approved as a medicine?

It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.

Does AOD9604 raise IGF-1 levels?

In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Network